<DOC>
	<DOC>NCT00936884</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety, efficacy, and tolerability of subcutaneous (injection beneath the skin) MOA-728 versus placebo in Asian Adult subjects with opioid-induced constipation and advanced illness</brief_summary>
	<brief_title>Study Evaluating The Efficacy And Safety Of Subcutaneous MOA-728 For The Treatment Of Opioid-Induced-Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<criteria>Men and women who are at least 18 years of age, and who have a diagnosis of advanced illness with anticipated life expectancy &gt;= 1 month; Is receiving a regular dose of opioids for the control of pain; Has a diagnosis of opioid induced constipation; Is on a stable laxative regimen. Has a known or suspected mechanical gastrointestinal obstruction, or any potential nonopioid cause of bowel dysfunction contributed to constipation; Has evidence of current fecal impaction; Has evidence of active diverticulitis, or peritonitis, or a history of bowel surgery within 30 days before test article administration; Has a boy weight less t han 27 kg Has any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study, or could preclude the evaluation of the subject's response.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Opioid Induced Constipation</keyword>
</DOC>